How Does Pegcetacoplan Work? Mechanism of Action, Per the Research

Short answer: the molecular target is complement component C3

Pegcetacoplan is a prescription medicine built around a small cyclic peptide derived from the compstatin family, chemically linked to a polyethylene glycol scaffold. Laboratory structural and biophysical work on compstatin analogues reported that these peptides bind native complement component C3 and its major activation fragment C3b, and that this binding interferes with the ability of convertase enzymes to cleave C3 (PMID 36127336). Because C3 occupies the central position in the complement cascade, a molecule that blocks C3 cleavage acts upstream of most complement effector functions rather than at a single downstream step, a point emphasised in a clinical review of C3 inhibition (PMID 36161656).

This page is for educational purposes only and is not medical advice; consult a licensed physician or another qualified prescribing clinician about any medical question. Nothing here describes how a medicine should be used, and no administration, preparation or schedule information is provided.

Where C3 sits in the complement system

Complement is a set of circulating and surface-bound proteins that form part of innate immunity. Reviews of complement biology in kidney disease described three activation routes, the classical, lectin and alternative pathways, that converge on enzyme complexes called C3 convertases (PMID 42074111). Those convertases cleave C3 into two fragments: C3a, a small peptide with inflammatory signalling activity, and C3b, a larger fragment that attaches covalently to nearby surfaces and tags them for recognition by phagocytes.

Surface-bound C3b then participates in an amplification loop by helping to form additional convertases, and it contributes to assembly of C5 convertases. A review of C3-directed drugs described how C5 cleavage releases C5a and C5b, with C5b initiating assembly of the membrane attack complex, the pore-forming structure that can lyse susceptible cells (PMID 36161656). That architecture explains why reviews describe C3 as a convergence point: events upstream of C3 differ between pathways, while nearly everything downstream depends on C3 cleavage products (PMID 42074111).

The established molecular mechanism

Binding to C3 and C3b

The best characterised element of pegcetacoplan pharmacology is target engagement. Structural work on the compstatin family reported that the peptides bind to a defined region of C3 and C3b and that specific residues within the cyclic peptide determine binding affinity and the mode of inhibition (PMID 36127336). That work was laboratory based, using purified proteins and structural methods rather than patients, and the authors framed it as defining the structural determinants shared across clinical compstatin analogues (PMID 36127336).

The functional consequence described in that literature is steric: with the peptide bound, the convertase cannot productively engage and cleave C3, so the substrate is effectively withdrawn from the reaction (PMID 36127336). A clinical review of C3 inhibitors described this as upstream blockade, contrasted with agents that act on C5 and therefore leave C3 cleavage intact (PMID 36161656).

Blocking two branches at once

Because C3 cleavage feeds both opsonisation and terminal pathway activation, reviews describe C3 inhibition as affecting two outputs simultaneously. A review of pegcetacoplan in paroxysmal nocturnal haemoglobinuria reported that inhibiting C3 limits deposition of C3 fragments on red cell surfaces and also reduces downstream terminal pathway activity (PMID 35441351). The same review framed this dual effect as the pharmacological rationale distinguishing proximal C3 inhibition from terminal complement blockade (PMID 35441351).

The pegylated peptide design

Pegcetacoplan is described in the literature as a pegylated form of a compstatin-derived peptide, with the polymer attached to the peptide core (PMID 35441351). Reviews of the compstatin class noted that chemical optimisation of these peptides, including modifications beyond the core sequence, was pursued to improve pharmacological properties relative to the original peptide (PMID 36127336). No dosing, preparation or administration details are presented on this page; those belong to the product labelling and to a prescribing clinician.

Downstream physiology in paroxysmal nocturnal haemoglobinuria

Paroxysmal nocturnal haemoglobinuria arises from an acquired mutation in haematopoietic stem cells that disrupts glycosylphosphatidylinositol anchors, so affected red cells lack the complement regulators normally tethered to the membrane. A review of pegcetacoplan in this condition reported that the resulting loss of surface regulation leaves red cells vulnerable to complement-mediated destruction (PMID 35441351).

Two destruction routes are described. Terminal pathway activation generates the membrane attack complex and intravascular lysis, while C3 fragments accumulating on the red cell surface mark those cells for removal by phagocytes in the liver and spleen, a process termed extravascular haemolysis. A review of C3 inhibition in the clinic reported that C3 fragment opsonisation became clinically visible once terminal pathway blockade was in widespread use, because surviving cells continued to accumulate C3 on their surfaces (PMID 36161656). That observation forms the mechanistic argument for intervening at C3, as described in the pegcetacoplan review (PMID 35441351).

Local complement inhibition in the eye

The second context in which pegcetacoplan appears in published pharmacology is geographic atrophy secondary to age-related macular degeneration. Reviews of inflammation in age-related macular degeneration reported that complement components and activation fragments are present within drusen and that genetic variation in complement regulatory genes is associated with disease risk, which supports complement activation as a contributor to retinal pigment epithelium and photoreceptor loss (PMID 37626902).

A 2025 review of dry age-related macular degeneration pathogenesis, models and emerging therapeutics described complement-directed agents as the leading pharmacological class evaluated in this setting, with intravitreal delivery used to concentrate the inhibitor within the eye rather than acting systemically (PMID 41516080). A pharmacology overview of macular degeneration agents similarly grouped complement-targeting compounds with other agents used in macular disease and summarised their intended site of action (PMID 31643677). These reviews described mechanism and rationale; they are not presented here as predictions about any individual outcome.

Established mechanism versus proposed mechanism

Investigational settings described in the literature

Several reviews place C3-directed inhibition among investigational approaches in conditions beyond the approved indications. A 2026 review of complement 3 glomerulopathy reported that dysregulated alternative pathway activity with glomerular C3 deposition defines the disease and discussed C3-level inhibition among targeted therapeutic strategies under evaluation (PMID 41670575). A review of complement targeting in IgA nephropathy described multiple complement pathway components as candidate drug targets in that disease and summarised the agents being studied at different levels of the cascade (PMID 38053977).

A 2025 review of atypical haemolytic uraemic syndrome described complement dysregulation on endothelial surfaces as the central mechanism and discussed complement inhibition as the therapeutic principle in that disorder (PMID 40436118). In haematology, a review of autoimmune haemolytic anaemias reported that complement activation contributes to red cell destruction in cold agglutinin disease and in some warm antibody cases, and listed complement inhibitors among newer therapeutic approaches being studied (PMID 39371250). An earlier review of autoimmune haemolytic anaemia pathogenesis similarly described C3 fragment deposition on red cells as a driver of extravascular clearance (PMID 33261023). These are described in the sources as areas of ongoing investigation rather than settled practice.

Infection Risk and Other Safety Considerations: What Studies Report

Because C3 cleavage products are central to opsonisation of bacteria, blocking C3 has predictable immunological consequences. A review of C3 inhibition in the clinic reported that susceptibility to encapsulated organisms is the principal safety concern for complement inhibitors and that vaccination strategies against encapsulated bacteria are a standard part of risk management with these agents (PMID 36161656). The review of pegcetacoplan in paroxysmal nocturnal haemoglobinuria likewise discussed infection risk and monitoring as part of the safety profile for proximal complement blockade (PMID 35441351).

For intravitreal complement inhibition, the 2025 review of emerging dry age-related macular degeneration therapeutics reported that safety and efficacy questions remain open for the complement-directed class and framed these agents within a still-evolving treatment landscape (PMID 41516080). A review of inflammation in age-related macular degeneration discussed the broader therapeutic landscape for geographic atrophy and the limits of current approaches (PMID 37626902). Full adverse event information for any approved product sits in the prescribing information and with the treating clinician.

What the mechanism does not explain

A mechanism of action describes molecular events; it does not predict outcomes for any individual. Reviews of complement biology in kidney disease noted that biomarkers linking complement activity to tissue injury remain an active research area, which limits how directly cascade-level changes can be translated into clinical expectations (PMID 42074111). In the retina, reviews reported that the relationship between complement activation, inflammation and photoreceptor loss involves multiple interacting processes rather than a single pathway (PMID 37626902).

Regulatory framing and where questions belong

Pegcetacoplan is a prescription medicine. Any application discussed in the literature that falls outside approved labelling is investigational and is described as such throughout this page. Published reviews addressed paroxysmal nocturnal haemoglobinuria (PMID 35441351) and geographic atrophy secondary to age-related macular degeneration (PMID 41516080) as the settings where the agent reached clinical use, while kidney and haematological applications were described as under study (PMID 41670575). Decisions about whether any medicine is appropriate, including suitability, monitoring and risks, belong in a conversation with a prescribing clinician who can review an individual medical history.

References

• Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors (Nature Communications, 2022)
• With complements: C3 inhibition in the clinic (Immunological Reviews, 2023)
• Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria (Clinical and Experimental Medicine, 2023)
• Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies (International Journal of Molecular Sciences, 2026)
• Complement 3 Glomerulopathy Revisited: Bridging Pathogenesis and Therapy in the New Era (Advances in Kidney Disease and Health, 2026)
• Targeting complement in IgA nephropathy (Clinical Kidney Journal, 2023)
• Atypical hemolytic uremic syndrome (Journal of Allergy and Clinical Immunology, 2025)
• Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy (Transfusion Medicine and Hemotherapy, 2024)
• New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1 (Journal of Clinical Medicine, 2020)
• The Role of Inflammation in Age-Related Macular Degeneration: Therapeutic Landscapes in Geographic Atrophy (Cells, 2023)
• Integrative Landscape of Dry AMD Pathogenesis, Models, and Emerging Therapeutic Strategies (International Journal of Molecular Sciences, 2025)
• Macular Degeneration Agents (StatPearls, 2012)